Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Ist Teil von
The New England journal of medicine, 2011-06, Vol.364 (26), p.2507-2516
Ort / Verlag
Waltham, MA: Massachusetts Medical Society
Erscheinungsjahr
2011
Quelle
MEDLINE
Beschreibungen/Notizen
In patients with advanced melanomas with the BRAF V600E mutation, vemurafenib produced a response in nearly half the patients; secondary skin tumors, arthralgia, rash, and fatigue were side effects. Dacarbazine produced a response in 6%.
Metastatic melanoma has a poor prognosis, with the median survival for patients with stage IV melanoma ranging from 8 to 18 months after diagnosis, depending on the substage.
1
In the United States last year, 8700 deaths from melanoma were projected, with an estimated rate of death of 2.6 in 100,000.
2
Rates of death from melanoma in Australia and New Zealand are slightly higher (3.5 in 100,000), whereas rates in Western Europe are slightly lower (1.8 in 100,000).
3
In phase 3 studies, dacarbazine, the only chemotherapeutic agent approved by the Food and Drug Administration for the treatment of metastatic melanoma, was . . .